Nektar Therapeutics Inc. (NKTR)
Summary
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atopic dermatitis [AD] and alopecia areata [AA]. The Phase 3 ZENITH AD program is underway, with three pivotal studies targeting moderate-to-severe AD subpopulations; topline data is expected mid-2028. REZPEG's differentiated mechanism aims for long-term disease control and safety advantages over current AD therapies, addressing a $37.3B global market.
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Nektar Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 2 | $52 | $142.56 | $90.56 | 174.15% |
| NA Nizar Araji National Bank Of Canada /FI/ | 22.78 | $1,291.99 | $1,742.21 | $450.22 | 34.85% |
| AG Anne Goffard Artal Group S.A. | 274,700 | $85.33M | $20.89M | -$64.45M | -75.52% |
| BG Bart Gancher Intech Investment Management LLC | 6,426 | $420,196.14 | $491,460.48 | $71,264.34 | 16.96% |
 Anthony Scaramucci SkyBridge Capital II LLC | 724,000 | $34.35M | $54.72M | $20.37M | 59.31% |
Nektar Therapeutics Inc. (NKTR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nektar Therapeutics Inc. ever had a stock split?
Nektar Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Howard W. Robin CEO | NASDAQ (CM) Exchange | 640268306 CUSIP |
| US Country | 63 Employees | - Last Dividend | 9 Jun 2025 Last Split | 3 May 1994 IPO Date |
Overview
Nektar Therapeutics is a prominent biopharmaceutical company specialized in the discovery and development of innovative therapies aimed at selectively modulating the immune system. With a primary focus on treating autoimmune disorders and chronic inflammatory conditions, Nektar Therapeutics leverages its expertise to create treatments that restore balance to the immune system. Operating both within the United States and internationally, the company's research and development efforts have led to the creation of a diverse pipeline of therapeutic candidates. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California, and maintains collaborative agreements with a range of leading pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, and Pfizer Inc., among others. This extensive network of collaborations underlines the company's commitment to advancing healthcare through innovation.
Products and Services
- NKTR-358: A pioneering therapeutic asset aimed at stimulating regulatory T (Treg) cells. This treatment is designed to correct the immune imbalance that underlies autoimmune diseases and chronic inflammatory conditions, representing a novel approach in the management of these disorders.
- PEG-CSF1: An engineered polyethylene glycol (PEG) modified hematopoietic colony-stimulating factor protein. PEG-CSF1 selectively modulates inflammation resolution processes and has broad applications across various therapeutic indications, including both acute and chronic inflammation. This versatility underscores its potential in addressing multiple health conditions.
- Tumor Necrosis Factor (TNF) Receptor Type II (TNFR2) Agonist Asset: A bivalent antibody molecule designed to selectively stimulate TNFR2 receptor activity. This asset avoids modulation of TNFR1 signaling, offering a targeted approach to stimulating the immune response in a way that could benefit patients with certain conditions.
- NKTR-255: An IL-15 receptor agonist that aims to enhance the body's natural cancer-fighting abilities. By boosting the immune system, NKTR-255 represents a promising tool in the fight against cancer, adding to the company's diverse portfolio of innovative therapies.
